Company intelligence / Profile preview
Elixirgen Therapeutics, Inc.
Baltimore, Maryland, USAelixirgentx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Elixirgen’s lead candidate EXG‑34217 is an autologous cell therapy using the ZSCAN4 gene to treat telomere biology disorders. Early Phase I/II data show successful ex vivo and in vivo telomere elongation in patients with TBDs without toxicity or need for immunosuppression—an unprecedented result in this field. The company has received FDA Orphan Drug, Rare Pediatric Disease, and RMAT designations for EXG‑34217. Preclinical work includes Bobcat mRNA™ technology showing promise in restoring dystrophin expression in a mouse model of Duchenne muscular dystrophy.
- Therapeutic areas
- HematologyRare Diseases
- Modalities
- mRNA therapeutics (including self-replicating RNA)Autologous cell therapy (CD34+ hematopoietic stem cells)Gene therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Hitachi Global Life Solutions – collaboration on microfluidic manufacturing of autologous cell therapies.
Beyond the preview
Go deeper on Elixirgen Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elixirgen Therapeutics, Inc..